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Angiogenesis, the sprouting of new blood vessels, is tightly mediated via a myriad of endogenous factors. A pro-angiogenic alteration
facilitates the formation of neovascular tumour networks, thereby providing mechanisms for uncontrolled growth. The kallikrein–kinin
system is postulated to be pro-angiogenic since its components have been detected in both endothelial cells and tumour tissue. No studies
have, however, focussed on the role of tissue kallikrein (TK) in human angiogenic endothelial cell– tumour interactions. This study has
optimised a challenge model whereby endothelial cells are presented with neuroblastoma metabolites, and vice versa. Image analysis of
immunoreactive TK revealed a dose-dependant, significant reduction of TK localisation within endothelial cells, while gene expression
remained unchanged, the latter determined by in situ RT-PCR. Neuroblastoma cells, when challenged with endothelial cell metabolites,
displayed no change in TK synthesis or localisation. Alterations in TK synthesis and/or storage by angiogenic endothelial cells may be
mediated by tumour-released signals and possibly indicate a shift from a proteolytic to a mitogenic function of TK. The challenge model
provides a relatively simple experimental system to study angiogenic factors in tumour–endothelial cell interaction, and is the first to localise
both TK and its mRNA within angiogenic endothelial and tumour cells.
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1. Introduction logical process whereby new blood vessels are formed [5]Normal growth and development of mammalian tissues
require an adequate blood supply [1]. To ensure survival,
cells must be within a diffusion limit distance of 100–200
Am from blood vessels [2]. Similarly, a tumour cannot
expand more than 1–2 mm3 before nutrients and waste
products become rate-limiting [3]. Therefore, as Folkman
[4] postulated three decades ago, a tumour mass has an
absolute requirement for neo-vascularisation in order to
expand and propagate. Angiogenesis is a cascading bio-0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.12.007
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E-mail address: naidoot@nu.ac.za (S. Naidoo).either from dividing progenitor endothelial cells [6] or
recruited from preexisting vasculature [7–9]. This cascade
occurs physiologically during foetal development and
female reproduction [8,10,11], pathophysiologically during
wound healing, and pathologically during rheumatoid
arthritis [12], diabetic retinopathies [11], duodenal ulcera-
tion, and the growth of solid and haematological tumours
[13]. To entice neo-vessel formation, tumour tissue and
other cells including macrophages, mast cells and lympho-
cytes (attracted to the tumour by chemotaxis) secrete pro-
angiogenic factors [7], which include basic fibroblast
growth factor (bFGF) [14,15], vascular endothelial growth
factor (VEGF) [16–18], angiogenin, transforming growth
factor h (TGF-h), thrombin, angiopoietin-1, pleiotropin
and scatter factor, amongst others. A number of proteolytic
components including the matrix-degrading metalloprotei-
nase (MMP) family [19] and the serine proteases (e.g.
kallikrein–kinin system) stimulate tumour invasion and
angiogenesis [20].
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loproteinases, which are required for extracellular matrix
(ECM) remodelling [21], and in vivo, TK activates pro-
gelatinase, an MMP involved in tumour mobility [21,22].
The release of TK in vivo can activate ECM-dependant
proteolysis, and TK mRNA has been demonstrated on
cultured bovine angiogenic endothelial cells [23]. In a
recent in vitro study by Yayama et al. [24], the TK gene
was found to be transcribed, expressed and secreted into
the medium of both human umbilical vein endothelial cells
(HUVECs) and human coronary artery endothelial cells.
These and other studies have investigated the kallikrein–
kinin system (KKS) in vascular endothelial cells and
various tumours, but few, if any, have addressed the role
of TK in the direct interaction between angiogenic endo-
thelial cells and tumour cells. This study proposes a model
to investigate the regulation of TK expression in endothe-
lial cells when directly challenged with tumour cell metab-
olites. The aim was to qualitatively and quantitatively
determine TK gene expression and protein translation,
respectively, in an in vitro HUVEC/neuroblastoma model.
This involved developing a challenge model, the use of in
situ reverse transcriptase polymerase chain reaction (IS RT-
PCR) to detect TK gene expression and the localisation of
TK using polyclonal antibodies.2. Materials and methods
2.1. Cell culture
The endothelial cell growth medium, designated
EBMR-2 Bulletkit comprised basal medium (modified
MCDB131), supplemented with human recombinant epi-
dermal growth factor (hEGF), human fibroblast growth
factor (hFGF), VEGF, ascorbic acid (vitamin C), hydro-
cortisone, human recombinant insulin-like growth factor
(long R3-IGF-1), heparin, foetal bovine serum (FBS),
gentamycin and amphotericin B. Tumour cell growth
medium consisted of Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS, 100 Ag/ml peni-
cillin/streptomycin/fungizone (PSF), 2 mM L-glutamine (L-
Glut), 2 mM sodium pyruvate and 3 Ag/ml vancomycin.
Neuroblastoma cells were initially grown in this supple-
mented DMEM before being weaned onto EBMR-2. All
cell culture reagents were purchased from BioWhittaker,
Walkersville, USA with the exception of L-Glut (Sigma
Chemical, St. Louis, USA).
2.2. Cell lines
HUVECs were obtained as primary cultures (Clonetics,
BioWhittaker), while the immortal neuroblastoma line (des-
ignated N2a) was obtained from Highveld Biological,
National Repository for Biological Material of the Cancer
Association of South Africa, Sandringham, South Africa.2.3. Passaging conditions
HUVECs and N2a were seeded onto 60-mm culture
dishes (Corning Costar, USA) at 5 103 and 1103 cells/
cm2, respectively, proliferated, harvested and passaged
according to supplier’s instructions. Only cell lines between
passages 3 and 9 were used.
2.4. Challenge model
HUVECs and N2a cells were plated onto 8-well cham-
ber slides (Iwaki, Japan), allowed to grow until approxi-
mately 60–70% confluent (typically 6–8 days), with fresh
medium changes initially after 24 h and then every 48 h.
Spent medium was extracted from one cell line, filtered
through 0.22-Am syringe filters (MillexR, Millipore, USA),
mixed in 10%, 25% and 50% ratios with fresh medium
(mixture termed ‘‘challenge medium’’) and used to feed the
other cell line, and vice versa. In this way, metabolites
released by one proliferating cell line were presented to the
other proliferating cell line, in a dose-controlled manner. A
maximum of 50% challenge medium dosage was deter-
mined to be the limit beyond which deleterious effects to
cell health and growth were observed (retraction of periph-
eral cell membrane structures, rounding-off of cell bodies
and retardation of growth and mitosis, as well as disintegra-
tions of some cell membranes). The cells were exposed to
the challenge medium for 24 h before being (serum-) cleared
with serum-free medium. After 20 h of incubation, the cells
were rinsed in cold Hanks Balanced Salt Solution (HBSS,
Mg2+ and Ca2+-free) and fixed in acetone/methanol (1:9, v/
v) for 20 min at  20 jC. Chamber slides were stored at 4
jC, under RNAse-free conditions, until immunochemistry
and mRNA assays could be performed.
2.5. TK immunochemistry
Bovine serum albumin (BSA) and Milk BlockerR
(casein protein) were obtained from Roche Molecular
Biochemicals, Mannheim, Germany. The avidin–biotin
(ABC) immunostaining kit (LSABR plus), liquid DAB
kit, von Willebrand’s Factor (vWF) and cytokeratin 19
(CK19) antibodies were purchased from Dako, UK. The
primary antibody, an anti-human polyclonal goat IgG
raised against a recombinant human TK, was isolated
and fully characterised for specificity and sensitivity, as
previously described [25].
2.5.1. Procedure
Challenged HUVECs and N2a cells (from challenge
model section above) were fixed in acetone/methanol (1:9,
v/v) for a further 5 min at  20 jC, incubated in Tris-
buffered saline (TBS, 150 mM NaCl, 50 mM Tris, pH 7.5)
for 5 min, and further incubated for 15 min in 7% BSA/TBS
(w/v), at room temperature (RT). Nonspecific sites on the
cells were blocked with 10% Milk BlockerR, diluted in 7%
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primary antibody (TK, CK19 and vWF were all diluted
1:100 in 10% Milk BlockerR) under humid conditions,
overnight at 4 jC. 10% Milk BlockerR was used to replace
the primary antibody for the negative control. Subsequently,
cells were washed with TBS and conjugated to a multi-
species biotinylated linker antibody, which was coupled to
horse-radish peroxidase–streptavidin complex (LSABR
plus) according to manufacturer’s instructions, at RT. The
reaction was precipitated with 3, 3V-diaminobenzidine
(DAB). The slides were counter-stained with haemotoxylin,
dehydrated through a dilution series of alcohol into xylene,
and finally mounted with nonaqueous mountant.
The method control used was paraffin-embedded normal
human submandibular gland, a known source of TK [26].
The tissue was probed for the presence of TK, according to
established immunochemistry protocols [27]. For negative
controls, the primary antibody was omitted and replaced
with 10% Milk BlockerR.
Results were viewed using a Leica DMLB bright-field/
phase-contrast microscope coupled to a Leica DC100 digital
camera (Leica, Heidelberg, Germany). 24-bit tagged image
format (TIFF) images were captured and converted to 8-bit
black and white images to enable regions of interest to be
selected. The grey scale intensity of specific label in the
digitised images was quantified using AnalySIS Pro image
analysis software (Soft Imaging Systems, Germany) using
predetermined threshold range-limited pixel/Am2 values.
2.6. In situ reverse-transcriptase polymerase chain reaction
(IS RT-PCR)
First Strand cDNA Synthesis Kitk was purchased from
Amersham Pharmacia Biotech, Buckinghamshire, UK. DIG
RNA Labelling KitR, Proteinase K, nitroblue tetrazolium/5-
bromo-chloro-indoyl-phosphate (NBT/BCIP), DIG Wash
and Block SetR (containing Milk BlockerR, 10 detection
buffer and maleic acid) and sheep anti-digoxigenin (DIG)
alkaline phosphatase-conjugated IgG were obtained from
Roche. Unless otherwise indicated, all solutions were made
up in 1% DEPC-dH2O (v/v). Synthetic TK RNA primers
hKLK1-160F [10 mM, 21-mer (5V-CTG TAC CAT TTC
AGC ACT TTC-3V)], hKLK1-742R [10 mM, 17-mer (5V-
GCC ACA AGG GAC GTA GC-3V)] and hKLK1-790R [10
mM, 21-mer, (5V-TCA CAT AAG ACA GCA CTC TGA-
3V)] were obtained from MWG-Biotech AG, Ebersberg,
Germany. Gene FrameR incubation chambers were pur-
chased from Advanced Biotechnologies, Surrey, UK.
2.6.1. Pretreatment
HUVECs and N2a from the challenge experiments
were fixed in freshly prepared 4% paraformaldehyde for
20 min at RT and then rinsed three times in TBS. Next,
partial protein digestion of the cells was performed in 0.01
M HCl for 10 min at RT. The walls of the chamber slides
were manually removed and 65-Al incubation chamberswere placed around each well to create an isolation
chamber. Cell membranes were partially permeabilised by
Proteinase K digestion for 20 min at 37 jC. Based on a
concentration range of 0.5 to 50 Ag/ml, an optimal
concentration of 1 Ag/ml Proteinase K was considered to
be the highest concentration at which cellular structure was
not compromised. This was followed by extensive rinsing
in cold TBS (3 10 min at 4 jC) to inactivate the enzyme.
Cells were then dehydrated through a graded series of
alcohol and air-dried.
2.6.2. Reverse transcriptase polymerase reaction (RT-PCR)
The reverse transcriptase solution was prepared accord-
ing to the manufacturer’s instructions using the First Strand
cDNA Synthesis KitR and the reverse primer hKLK1-790R.
Briefly, for each reaction, a mix containing 4-Al 10 AM
dithiothreitol (DTT), 4-Al hKLK1-790R reverse primer, 44-
Al DEPC-dH2O, and bulk kit mix (without Ca2+ and Mg2+)
was prepared. Sixty microliters of this reaction mixture was
placed onto the cells in each incubation chamber and the
chamber covered with a plastic coverslip. Slides were
placed in the humid chamber of a Hybaid OmniSlide Flat-
block (Hybaid, Middlesex, UK) and incubated at 37 jC for
150 min.
The spent reaction mixture was then carefully removed
and replaced with 60 Al of the PCR1 mixture containing 5-
Al 10Taq buffer (with MgCl2), 2 Al each of hKLK1-160F
and hKLK1-790R primers, 1-Al Taq DNA polymerase (5 U/
Al), 10-Al 10 mM dNTP mix and 40-Al DEPC-dH2O. A
plastic coverslip was placed over the cells and the incuba-
tion chamber sealed to prevent the cells from dehydrating.
Thermal cycling was performed on a Hybaid OmniSlide
Flatblock using the following conditions: initial denatur-
ation (92 jC for 2 min), followed by 15 cycles of denatur-
ation (92 jC for 1 min each), annealing (55 jC for 1 min)
and extension (72 jC for 1 min), and a final extension (72
jC for 2 min). The PCR1 mixture was then carefully
removed and replaced with 60 Al of the PCR2 mixture
containing 5-Al 10 Taq buffer (with MgCl2), 2 Al each of
hKLK1-160F and hKLK1-742R, 1-Al Taq DNA polymerase
(5 U/Al), 10-Al 10 PCR DIG labelling mix (DIG RNA
Labelling KitR) and 30-Al dH2O. Again, a plastic coverslip
was placed over the incubation chamber and sealed. Ther-
mal cycling was performed as follows: initial denaturation
(92 jC for 2 min), followed by five cycles of denaturation
(92 jC for 1 min each), annealing (55 jC for 1 min) and
extension (72 jC for 1 min), and a final extension (72 jC
for 2 min).
After thermal cycling, the coverslip was carefully re-
moved and the tissue washed in 2 saline sodium citrate
(SSC) at 37 jC for 30 min, 1 SSC at 55 jC for 20 min,
0.5 SSC at 55 jC for 20 min and finally in 0.5 SSC at
55 jC for 20 min. Negative control reactions were also
carried out in which the primers were omitted from the
reverse transcriptase and PCR reactions and the final vol-
ume of the solutions compensated with DEPC-dH2O.
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amplificants
Following the SSC washes, the slides were washed twice
in TBS and blocked with 10% blocking reagent, (DIG Wash
and Block SetR) for 15 min at RT. The cells were then
incubated with a polyclonal sheep anti-DIG IgG alkaline
phosphatase conjugate, diluted 1:500 in 10% blocking
reagent, overnight at 4 jC. Slides were washed twice in
TBS and covered with a freshly prepared NBT/BCIP
solution, diluted 1:50 in 1 detection buffer (DIG Wash
and Block SetR). The chromogen was allowed to develop
in the dark at RT, until a purple-black-coloured precipitate
was distinct. The slides were washed extensively in tap
water, counter-stained with haematoxylin, dehydrated and
mounted. Results were viewed using a Leica DMLB bright-
field/phase-contrast microscope coupled to a Leica DC100
digital camera.
2.7. Statistical analysis
All data obtained from image analysis of immunoreactive
TK-labelled cells in the challenge model (see TK immuno-
chemistry section above) were expressed as meanF S.D.
(Fig. 2). All labelling experiments were done in triplicate.
For images to be analysed, at least five fields in each
experiment were selected and imaged, and cells in these
were selected approximately for size and shape. The Stu-
dent’s t test (unequal variance) was used to assess statistical
significance (P < 0.05).
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3.1. Phenotypic growth profiles of cells in the challenge
model
The phenotypic profile of unchallenged HUVECs
showed initial lag-phase growth after seeding, followed
by exponential growth. Cells in close proximity to one
another extended tentative pseudopodia-like sprouts. Three
to four days after initial seeding, some cord-like structures
(CLS) were established with cells lining up end-on-end. By
the 5th to 6th day post-seeding, 60–70% sub-confluency, in
addition to CLS, was noted. In the challenge model, no
considerable number of HUVECs or N2a succumbed to
necrosis (complete disintegration of cell membranes) or
apoptosis (retraction of peripheral cell membrane structures,
membrane blebbing or ‘‘rounded-off’’, condensation of
nuclei). The visual growth of HUVECs, subjectively com-
pared to non-challenged cells, did not appear to be mark-
edly different in response to the tumour cell metabolite
concentrations [Tu].
N2a cells grown on two-dimensional surfaces did not
exhibit CLS, but instead formed monolayer clusters at sub-
confluency, with cells appearing fibroblastic. The different
endothelial cell metabolite concentrations [En] in the chal-lenge model did not appear to alter the growth patterns or
growth rate of the N2a cells.
3.2. Immunochemical staining for TK
3.2.1. Immunochemistry controls
The TK positive method control showed labelling within
the duct-lining epithelial cells but not the acini in the
submandibular gland (Fig. 1a) [25,26,28]. Unchallenged
HUVECs and N2a cells served as cell culture controls.
Positive DAB staining was observed within HUVECs
(labelled with vWF) and N2a (labelled with CK-19),
respectively (Fig. 1b and c). In the method controls the
primary antibody (TK, vWF or CK-19) was replaced with
dilution buffer, and both HUVECs and N2a showed no
nonspecific label (Fig. 1d and e). To confirm endothelial cell
function in the challenge model, 50% challenged HUVECs
demonstrated vWF labelling (Fig. 1f) that was similar to the
unchallenged endothelial cells (Fig. 1b).
3.2.2. TK immunoreactivity in unchallenged HUVECS
This aspect of the model served as the cell culture
control, since these endothelial cells were not exposed to
challenge medium. Unchallenged HUVECs at the periphery
of the sub-confluent growth areas demonstrated extensive
TK labelling, especially within the cytoplasm of cells (Fig.
1g). TK localisation was most convincing on the leading
edges of advancing cells that presented cell-to-cell contact
extensions, or locomotor extensions along the growth sur-
face. Cells maintaining CLS exhibited TK mainly in the cell
body structures. Visually, approximately 40% of unchal-
lenged HUVECs, per microscopic field, specifically labelled
for TK.
3.2.3. TK in challenged HUVECS
Decreased TK immuno-detection patterns emerged as the
[Tu] delivered to HUVECs increased. TK labelling in the
10% challenged HUVECs was observed along cells forming
CLS, while some HUVECs that formed confluent regions
did not label at all (Fig. 1h). HUVECs incubated with the
25% challenged medium also demonstrated TK immuno-
label along the CLS in the cytoplasm and extensions
between cells (Fig. 1i). The 50% challenged HUVECs
visually demonstrated a reduced perinuclear labelling inten-
sity (Fig. 1j). The increase in [Tu] thus appeared to elicit a
decrease in TK immuno-localisation in endothelial cells.
Image analysis revealed a reduction in the staining
intensity gradients with increasing [Tu] concentrations
(Fig. 2a). Despite this reduction in immunoreactive TK,
there was no visible alteration of the growth/proliferation
patterns of challenged HUVECs when compared with
growth patterns of unchallenged HUVECs. ‘Rounding off’
of endothelial cells in culture due to retraction of extensions
and condensation of nuclei, visual markers of apoptosis, was
not markedly increased, and did not favour either challenged
or unchallenged HUVECs.
Fig. 1. Immunohistochemical changes in the challenge model. Positive label is depicted as a brown precipitate (DAB), and scale bars on each image = 300 Am.
Normal human submandibular gland, used as TK positive tissue control (Fig. 1a, 200), demonstrated labelling in glandular structures (blue arrows) and an
absence of label within the acini (black arrowhead). HUVEC and N2a positive cell culture controls demonstrated vWF and CK-19 label (blue arrows) in b
( 400) and c ( 400), respectively. HUVEC and N2a negative cell culture method controls demonstrated complete absence of TK in d ( 400) and e ( 400),
respectively. To verify that endothelial cell function was retained, perinuclear staining for vWF (blue arrows) was demonstrated in 50% challenged HUVECs
(f, 400). In the HUVEC challenge model, TK staining (blue arrows) was demonstrated within unchallenged HUVECs (g, 400) and challenged HUVECs
[(10%, h, 200), (25%, i, 400) and (50%, j, 400)]. Examples of CLS formation are demonstrated in h and i (black arrows). Also note the absence of label
in an adjacent semi-confluent region (h, blue arrowhead). In the N2a challenge model, TK immunolabelling (blue arrows) was demonstrated within
unchallenged N2a (k, 400) and challenged N2a [(10%, l, 400), (25%, m, 400) and (50%, n, 400). Note an actively dividing cell with perinuclear
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Unchallenged N2a demonstrated TK staining in the
cytoplasm of most cells (Fig. 1k). The increase in [En]
did not appear to potentiate or diminish TK labelling [Fig. 1l
(10% challenged), Fig. 1m (25% challenged) and Fig. 1n
(50% challenged)]. Challenged N2a cultures did not
staining (m, blue arrow).exhibit any alteration in growth response to [En]. In both
the challenged and unchallenged models, cells that grew in
isolation displayed TK within their entire cell bodies, while
cells that were undergoing mitosis (Fig. 1m and n) or
exhibiting extensor-like projections showed perinuclear
localisation of TK.
Fig. 2. Dose-dependent effects of metabolites on TK label-intensity in HUVECs and N2a in the challenge model. (a) depicts the dose-dependant effects of
tumour metabolites on the labelling intensity of TK, when presented to HUVECs; while (b) represents the dose-dependant effects of HUVEC metabolites on
the labelling intensity of TK within N2a. Digital image analysis of TK-DAB labelling intensity of unchallenged cells was statistically compared with
th a and b). Statistical significance was represented by P< 0.05.
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Image analysis histograms of TK labelling intensities
(Fig. 2a and b) indicated a statistically significant decrease
when 50% challenged HUVECs were compared with un-
challenged HUVECs (P= 1.8 10 11), 10% challenged
HUVECs (P= 3.9 10 6) and 25% challenged HUVECs
(P= 2 10 3). Thus, the overall trend appeared to be a
significant decrease in TK immunoreactivity as the HUVECs
became increasingly challenged with medium containing
tumour metabolites.
The dose-dependent effect of HUVEC-conditioned me-
dium did not statistically change the mean labelling inten-
sities of the exposed neuroblastoma cells, except between
the 25% and 50% challenged N2a (P= 6 10 3, Fig. 2b) .
There was, in fact, a slight increase in mean TK intensity as
the [En] ratio increased to 25%, but the difference was not
conditioned medium challenged cells (shown in separate text blocks for bostatistically significant. Therefore, there did not appear to be




In the human submandibular gland tissue method control,
positive label for TK mRNA was demonstrated in the
cytoplasm of the duct cells (Fig. 3a). In the negative tissue
method control, the reverse primer hKLK-790R was omitted
during reverse transcriptase, and so were both reverse
(hKLK-742R) and forward (hKLK-160F) primers during
PCR. Thus, in the negative method controls, there was an
absence of TK mRNA label in the cytoplasm of the duct
cells but some artifactual labelling of nuclei (Fig. 3b). This
Fig. 3. Detection of TK mRNA by IS RT-PCR. TK mRNA was visually represented by a purple/black precipitate, and scale bars on each image = 300 Am.
Human submandibular gland positive method control (a, 200) demonstrated cytoplasmic TK mRNA in duct cells (blue arrows), while the negative method
control showed a lack of TK mRNA cytoplasmic staining (b, 200). Artifactual labelling observed within the nuclei (visually distinct in negative control, d)
was due to nicked nuclear DNA fragments, cleaved by DNAse, being repaired by Taq DNA polymerase, and incorporating DIG-dUTP into the repaired DNA,
which was subsequently observed as nonspecific labelling within the nuclei in both method controls and positively labelled cells. HUVEC and N2a cell culture
negative controls [c ( 400) and d ( 400), respectively] demonstrated an absence of cytoplasmic TK mRNA, in which all primers were omitted in both the
reverse transcriptase and PCR reactions. TK mRNA labelling (blue arrows) was demonstrated within unchallenged HUVECs [(endothelial cell culture positive
control); e, 400], challenged HUVECs [(10%, f, 200), (25%, g, 400) and (50%, h, 200)]; as well as in unchallenged N2a [(tumour cell culture positive
control); i, 400] and challenged N2a [(10%, j, 400), (25%, k, 400) and (50%, l, 400)]. (h) demonstrated cells clumping together and extensive label
over the entire cell body (black arrow). Note that insets in e ( 400) and f ( 400) demonstrate peripheral mRNA label in individual endothelial cells (blue
arrows).
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the PCR reaction whereby the Taq DNA polymerase is
known to screen nuclear DNA for nicks caused by DNAse,
and repair these fragments. In doing so, DIG-dUTP from the
nucleotide pool would be incorporated into the repairednuclear strands and this would account for the nonspecific
nuclear labelling in both the negative and positive control
tissue. Tissue culture negative method controls for HUVECs
and N2a cells also demonstrated no cytoplasmic mRNA
labelling, although nonspecific nuclear staining was evident
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N2a cells served as positive cell culture controls for IS RT-
PCR and both cell types demonstrated TK mRNA label
within their cytoplasm (Fig. 3e and i).
3.3.2. TK mRNA in HUVECS
Both unchallenged (Fig. 3e) and challenged HUVECs
[Fig. 3f (10%), g (25%) and h (50%)] exhibited cytoplasmic
TK mRNA, and nonspecific nuclear labelling. There was no
differing pattern of mRNA labelling amongst the various
challenged cells, and while most HUVECs demonstrated
cytoplasmic label (Fig. 3e and f), many also showed label
along the cell body periphery (insets, Fig. 3f and g) and not
in the cellular extensions. This could be due to the presence
of transcriptional machinery within the cell body rather than
the cellular extensions. In areas of cell clumping, the mRNA
appeared to be spread throughout the cell body (Fig. 3h),
possibly reflecting the effect of overgrowth. CLS did not
exhibit atypical label patterns compared with individual
cells (Fig. 3g). In general, no differing intensity of TK
mRNA label could be ascertained possibly because this type
of IS RT-PCR is not quantitative. The ratio of labelled cells
to total cells was determined by taking the mean of five
different fields of view, for each challenge and counting the
cells. This approximation revealed the presence of TK
mRNA in 30% to 50% of both unchallenged and challenged
HUVECs.
3.3.3. TK mRNA in neuroblastoma cells
The extent and intensity of mRNA localisation in N2a
cells appeared to be greater than that observed in HUVECs.
Within N2a cells there was no discernable difference in the
pattern of staining between the unchallenged (Fig. 3i) and
challenged cells [Fig. 3j (10% challenged), Fig. 3k (25%
challenged) and Fig. 3l (50% challenged)], and cytoplasmic
TK mRNA label was found in virtually all cells, irrespec-
tive of whether they were solitary or in close contact with
each other. In addition, the cellular localisation of TK
mRNA extended throughout the cell body and the extensor
regions.4. Discussion
TK processes high and low molecular weight kininogen
(HK/LK) to liberate the bioactive kinin peptides, bradykinin
(BK) and kallidin. The actions of kinins result in the
production of nitric oxide (NO) and prostacyclin (PGI2)
[26] which increase vascular permeability and cause vaso-
dilation [29]. Kinins are also known to promote cell prolif-
eration and tissue regeneration by influencing DNA
synthesis and mitosis [30]. This present study has success-
fully demonstrated both immunoreactive TK and TK
mRNAwithin the cytoplasm of angiogenic endothelial cells
and neuroblastoma cells, indirectly interacting in culture.
These results corroborate prior work where the TK gene wasshown to be expressed and secreted in both HUVECs and
human coronary artery endothelial cells [24]. In addition,
TK has been previously shown in various tumour cells of
the breast [31], oesophagus [32], pituitary [33], astrocytes
[34] and cultured gastric carcinoma cells [35]. Recent
studies have demonstrated TK mRNA on bovine angiogenic
endothelial cells [23] and non-angiogenic HUVECs [24].
The present study introduces new findings that demonstrate
TK mRNA transcription within angiogenic endothelial cells
and N2a cells in culture.
The challenge model demonstrates that as the [Tu] in the
HUVEC medium increases, there is a significant decrease in
immunoreactive TK labelling. This may be due to one or a
combination of the following effects of tumour metabolites
on endothelial cells: (i) a reduction in TK synthesis; (ii) an
increase in TK secretion (experiments are currently under-
way to examine this hypothesis); and/or (iii) accelerated
conversion of pro-TK to active TK, leading to an increase in
kallikrein functional activity and a subsequent decrease in
immunoreactive TK due to half-life turnover (Fig. 4). The
latter effect is supported by the ability of TK to act as a
mitogen [30] and as a protease in ECM degradation.
The TK-secretion supposition may be answered, in part,
by a study by Stadnicki et al. [36], who have shown that
there is a significant decrease in TK secretion by granulo-
matous cecal tissue, in culture, in an enterocolitis-induced
rat model. Further, they reported no significant alteration in
intestinal TK mRNA levels but decreased plasma levels of
kallikrein-binding protein (a rat analogue of kallistatin, a TK
inhibitor). Thus, they postulated that significant amounts of
TK would have been released in vivo by the cells during
inflammation. In a later study advocating TK release,
Stadnicki et al. [37] have found a significant decrease in
TK levels in inflamed human intestinal tissue in ulcerative
colitis and Crohn’s disease. Since this present study indi-
cates no change in TK mRNA transcription, at this point it
may be presumed that the decrease in immunoreactive TK is
not due to a decrease in TK synthesis.
TK activates pro-gelatinases [21] and processes pro-
metalloproteinases required for ECM remodelling [22], and
thus lends itself to a role in promoting tumour invasive-
ness. The serine proteinase inhibitor (serpin) kallistatin has
been found to inhibit angiogenesis, both in vivo and in
vitro [38], and this supports a pro-angiogenic function for
TK. Further, the inhibition of TK using a synthetic
inhibitor has also been shown to suppress in vitro tumour
invasiveness [39].
High-molecular weight kininogen (HK) can specifically
bind to endothelial cells, which then serves as a receptor
complex for prekallikrein binding, and the activation of the
latter to kallikrein results in the release of bradykinin (BK)
from HK and the formation of kallikrein-cleaved HK (HKa).
It was also demonstrated that HKa competitively binds to
domains 2 (D2) and 3 (D3) of the urokinase plasminogen
activator receptor (uPAR)—an adhesion receptor for vitro-
nectin [40]. Asakura et al. [41] showed that HKa is anti-
Fig. 4. Proposed subcellular effects of tumour metabolites on TK in HUVECs. Neuroblastoma tumour metabolites may cause accelerated activation of pro-TK
to functional TK in challenged HUVECs, resulting in increased proteolytic release of BK from HK, with no concomitant change in TK gene expression. This,
together with extracellular release of pro-angiogenic TK, possibly accounts for the reduced cellular immunolocalisation of TK. TK, BK, as well as HK are pro-
angiogenic, while HKa and HKa D5 are anti-angiogenic and anti-adhesive. The latter effects may be due to the competitive binding of HKa to uPAR (a
vitronectin-adhesion receptor) and the actions of HKa D5 on the endostatin-associated, membrane-bound protein tropomysin. Both active TK and BK can
regulate tumour cell proliferation due to their mitogenic capacity.
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[42], in a series of experiments, showed that D5 of HK as
well as HKa inhibit endothelial cell proliferation and in vitro
angiogenesis, whereas HK itself was not anti-angiogenic.
Similar experiments by Zhang et al. [43] found that HKa
and a specific HK D5 peptide, but not HK, low-molecular
weight kininogen (LK), BK or BK antibodies, inhibited
proliferation and induced apoptosis of endothelial cells in a
Zn2+-dependant manner. This is in contrast to a recent study
by Colman et al. [44] who found that HK and LK (via BK
release), and BK itself are pro-angiogenic. In addition,
Zhang et al. [45] have found that in HKa-induced apoptosis,
D5 is involved in binding to the surface-bound cytoskeletal
protein tropomysin, which has been shown to mediate the
effects of the potent antiangiogenic factor endostatin, lead-
ing one to consider that HKa may also be involved in
tropomysin-mediated pro-angiogenic signal transduction
events.
Challenged N2a cells showed no alteration in TK mRNA
transcription or TK synthesis, and endothelial cell metabo-
lites appeared to have little or no effect on the rate of
neuroblastoma cell proliferation. It was evident, however,
that compared with endothelial cells there was a greater
transcription of TK mRNA in N2a cells, probably driven by
extremely productive tumour genetic expression. This may
explain the indiscriminate localisation of TK mRNA in
neuroblastoma cell bodies, which did not necessarily favour
peripheral sprouts. Thus, while not outwardly toxic to the
neuroblastoma cells, the endothelial cells metabolites mayhave some other effect on neuroblastoma cell metabolism.
The ability of TK to up-regulate mitosis and DNA synthesis
may be a consideration within aggressively proliferating
tumour tissue.
This study has successfully set up a challenge model
whereby tumour metabolites, released into the culture
medium, are presented to human endothelial cells, without
having a deleterious effect on cell viability. Since both
tumour cells and endothelial cells are grown in the same
culture medium, the effects of supplemented growth fac-
tors are negligible. In addition, the effect of serum proteins
on the TK labelling can also be discounted since, prior to
fixation, cells were serum-starved. A limitation of this
model is the absence of an ECM and factors associated
with it, since conformationally altered proteins (and their
fragments) derived from ECM as well as other signalling
cues have been reported to play a role in angiogenesis
[45,46]. Another system currently being optimised is a
three-dimensional basement membrane complex (Matrigel)
applied to the challenge model. This will address the role
of TK in HUVEC–tumour interactions supported by an
ECM.
The interplay between endothelial cells and tumour cells
in regulating TK warrants further investigation. Since kal-
likrein appears to have multi-faceted functions in tumouri-
genesis and angiogenesis, empirical models need to be
established to clearly define these relationships. To con-
clude, the challenge model forms an important experimental
mechanism in elucidating the role of protein systems in
S. Naidoo et al. / Biochimica et Biophysica Acta 1691 (2004) 117–127126angiogenesis, and applications could encompass a variety of
candidate proteases and hormones.Acknowledgements
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